• Explore /
  • Poster
  • / RAF-inhibitor rechallenge therapy in BRAF aberrated pan-cancers: RE-RAFFLE study.

RAF-inhibitor rechallenge therapy in BRAF aberrated pan-cancers: RE-RAFFLE study.

Abstract Poster

Authors

null

Blessie Elizabeth Nelson

The University of Texas MD Anderson Cancer Center, Houston, TX

Blessie Elizabeth Nelson , Jason Roszik , CARMELIA MARIA NOIA BARRETO , Mirella Nardo , Jibran Ahmed , Erick Campbell , Amber Johnson , Sarina A. Piha-Paul , Isabella Claudia Glitza , Shiao-Pei S. Weathers , Maria E. Cabanillas , Milind M. Javle , Funda Meric-Bernstam , Vivek Subbiah

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3105)

DOI

10.1200/JCO.2023.41.16_suppl.3105

Abstract #

3105

Poster Bd #

303

Abstract Disclosures

Similar Posters

First Author: Mario Machado Lopes

First Author: Tamara A. Sussman

First Author: Antonio Tito Fojo

Poster

2021 ASCO Annual Meeting

Survival outcomes associated with fewer combination ipilimumab/nivolumab doses in advanced-stage melanoma.

Survival outcomes associated with fewer combination ipilimumab/nivolumab doses in advanced-stage melanoma.

First Author: Vincent T Ma